CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Once-weekly Isoniazid and Rifapentine for 12 Weeks for the Treatment of Latent Tuberculosis Infection: Clinical Utility and Cost-Effectiveness

Last updated: August 14, 2020
Project Number: RA1129-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Reference List
Result type: Report

Question

  1.  What is the clinical utility of once-weekly isoniazid and rifapentine for 12 weeks for the treatment of latent tuberculosis infection?
  2.  What is the cost-effectiveness of once-weekly isoniazid and rifapentine for 12 weeks for the treatment of latent tuberculosis infection?

     

Key Message

Two systematic reviews with meta-analyses, one systematic review with a network meta-analysis, five randomized controlled trials and ten non-randomized studies were identified regarding the clinical utility of once-weekly isoniazid and rifapentine for 12 weeks for the treatment of latent tuberculosis infection. Additionally, two economic evaluations were identified regarding the cost-effectiveness of once-weekly isoniazid and rifapentine for 12 weeks for the treatment of latent tuberculosis infection.